10.1200/jco.2017.35.15_suppl.4004
10.1200/jco.2017.35.15_suppl.4004 · doi-reference
TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG
10.1245/s10434-017-5830-6 · doi-reference
10.1200/jco.2016.34.15_suppl.4000
10.1200/jco.2016.34.15_suppl.4000 · doi-reference
Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection
10.1016/j.ijrobp.2012.07.2378 · doi-reference
10.1002/cncr.30692
10.1002/cncr.30692 · doi-reference
Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer
10.1016/j.ijrobp.2006.09.012 · doi-reference
Use of normal tissue complication probability models in the clinic
10.1016/j.ijrobp.2009.07.1754 · doi-reference
Multicenter phase 2 study of peri-irradiation chemotherapy plus intensity modulated radiation therapy with concurrent weekly docetaxel for inoperable or medically unresectable nonmetastatic gastric cancer
10.1016/j.ijrobp.2017.03.032 · doi-reference
Trends in the surgical treatment of gastric adenocarcinoma
10.1245/s10434-013-3314-x · doi-reference
A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer
10.1007/s00280-010-1256-6 · doi-reference
Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114)
10.1200/jco.2008.20.3745 · doi-reference
Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen)
10.1007/s12032-010-9741-7 · doi-reference
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
10.1016/s1470-2045(13)70021-4 · doi-reference
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2
10.1200/jco.2009.25.8376 · doi-reference
Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection
10.1111/j.1743-7563.2010.01331.x · doi-reference
Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients
10.1016/s0399-8320(05)80688-8 · doi-reference
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid
10.1200/jco.1986.4.5.685 · doi-reference
Proton therapy in adjuvant treatment of gastric cancer: planning comparison with advanced x-ray therapy and feasibility report
10.3109/0284186x.2014.912351 · doi-reference
Incorporating breath holding and image guidance in the adjuvant gastric cancer radiotherapy: a dosimetric study
10.1186/1748-717x-7-98 · doi-reference
A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection
10.1016/j.radonc.2012.08.024 · doi-reference
Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer
10.1007/s00066-013-0309-2 · doi-reference
Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer
10.1016/j.ijrobp.2008.12.036 · doi-reference
Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery
10.1007/s00432-011-1085-y · doi-reference
Does adjuvant chemoradiotherapy improve the prognosis of gastric cancer after an r1 resection? Results from a Dutch cohort study
10.1245/s10434-014-4032-8 · doi-reference
Comparison of dosiology between three dimensional conformal and intensity-modulated radiotherapies (5 and 7 fields) in gastric cancer post-surgery
10.1007/s11596-013-1193-9 · doi-reference
Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer
10.1002/cncr.25246 · doi-reference
IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer
10.1016/j.radonc.2014.08.039 · doi-reference
IMRT for adjuvant radiation in gastric cancer: A preferred plan?
10.1016/j.ijrobp.2005.03.013 · doi-reference
3D conformal radiotherapy for gastric cancer–results of a comparative planning study
10.1016/j.radonc.2005.01.006 · doi-reference
Radiation therapy oncology group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer
10.1016/j.ijrobp.2012.01.022 · doi-reference
Interobserver variation of clinical target volume delineation in gastric cancer
10.1016/j.ijrobp.2009.06.023 · doi-reference
